Apligraf denied as non-formulary by Cigna?

Cigna's specific coverage criteria for apligraf are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Apligraf as Non-Formulary

Apligraf (a bilayered living cell-based wound therapy) is classified as a medical benefit — billed under a procedure or product code — rather than a pharmacy benefit for most Cigna plans. A non-formulary denial in this context typically means either that Apligraf is not listed on the medical-benefit coverage schedule for the plan, or that the plan requires a formulary exception because a lower-cost wound-care alternative is the default covered option. Understanding which pathway Cigna's denial is using determines how the exception request should be framed.

## Why This Denial Is Appealable

Formulary and benefit exceptions exist precisely for situations where the default covered option is clinically inadequate for a specific patient. If conservative wound-care alternatives have been tried and failed, the clinical record supports an exception. Under ACA §2719 and ERISA §503, you have the right to a full-and-fair internal review of any coverage determination, and to external review by an independent IRO if the internal appeal fails. The treating wound-care clinician's documented rationale is the cornerstone of that process.

## Federal Appeal Framework

• Formulary/benefit exception request: File this simultaneously with the internal appeal or as a separate, parallel request — whichever Cigna's denial letter directs.
• Internal appeal (ERISA §503 / ACA §2719): Submit within the timeframe on the denial letter.
• External review: Available through an accredited IRO after final internal denial, generally within four months of that decision.
• Expedited review: Request if wound severity poses an imminent risk of limb-threatening complication or hospitalization, with written documentation of urgency.

## Concrete Appeal Steps and Timeline

1. Confirm from the denial letter whether this is a pharmacy-benefit formulary issue or a medical-benefit coverage issue; the exception pathway differs. 2. Obtain Cigna's coverage policy for Apligraf and identify what the plan does cover for chronic wound care. 3. Have the treating clinician document why covered alternatives are clinically inadequate for this patient's specific wound. 4. Submit the exception request and internal appeal together with wound records, prior-treatment history, and the prescriber letter. 5. Request expedited review if wound acuity supports it. 6. If denied internally, file for external IRO review at once.

## Documentation to Gather

• Prior wound-care treatment record: Dated documentation of every conservative or formulary wound-care modality attempted, with recorded outcomes — showing why those alternatives did not produce adequate healing.
• Wound status records: Serial photographs, wound measurements, and wound-bed descriptions at the time Apligraf is requested.
• Prescriber letter: Documents why Apligraf is the appropriate next step for this patient and why formulary alternatives are insufficient, citing specific chart findings.
• Cigna coverage policy and formulary documents: Both the current medical-benefit policy for Apligraf and the plan's formulary (or covered-products list) to understand the specific gap being appealed.
• Diagnosis and comorbidity documentation: Chart confirmation of wound type and any factors that affect healing and differentiate this patient from the general population.

## Criteria-Mapping Structure

Obtain Cigna's formulary or benefit-exception criteria for wound-care products. List each criterion in a table; in the adjacent column, document the chart evidence that satisfies it — dates of prior treatment, wound measurements, recorded outcomes. This structure demonstrates that the exception is clinically justified and not merely a preference for a more expensive product.